Drug & intervention
telmisartan
RxCUI 73494
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
Telmisartan
Telmisartan, sold under the brand name Micardis among others, is a medication used to treat high blood pressure and heart failure. It is a reasonable initial treatment for high blood pressure. It is taken by mouth. Common side effects include upper respiratory tract infections, diarrhea, and back pain. Serious side effects may include kidney problems, low blood pressure, and angioedema. Use in pregnancy may harm the baby and use when breastfeeding is not recommended. It is an angiotensin II receptor blocker and works by blocking the effects of angiotensin II. Telmisartan was patented in 1991 and came into medical use in 1999. It is available as a generic medication. In 2023, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions. It is available in combination with hydrochlorothiazide as telmisartan/hydrochlorothiazide; with cilnidipine as telmisartan/cilnidipine; and with amlodipine as telmisartan/amlodipine.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
40 shownEdmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform TrialNCT07207057 · 2025-09-12
RECRUITINGTelmisartan in Prostate CancerNCT06168487 · 2024-04-22
RECRUITINGTelmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer PatientsNCT07370506 · 2026-02-01
NOT_YET_RECRUITINGA Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic SyndromeNCT05843162 · 2023-06-01
UNKNOWNEfficacy and Safety of Telmisartan Compared With LosartanNCT06431477 · 2023-04-19
UNKNOWNTelmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney FunctionsNCT04736329 · 2021-02-01
COMPLETEDDetermining the Optimal Dose of AD-209 in Patients With Essential HypertensionNCT04218552 · 2020-02-25
COMPLETEDEvaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/AmlodipineNCT04158076 · 2020-01-23
COMPLETEDClinical Efficacy of Telmisartan in Reducing Cardiac Remodeling Among Obese Patients With HypertensionNCT03956823 · 2019-08-01
UNKNOWNEvaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and TelmisartanNCT03872232 · 2019-02-26
COMPLETEDRotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)NCT03504566 · 2017-11-15
WITHDRAWNReplication of the TRANSCEND Antihypertensive Trial in Healthcare Claims DataNCT04354376 · 2017-09-22
COMPLETEDReplication of the ONTARGET Antihypertensive Trial in Healthcare Claims DataNCT04354350 · 2017-09-22
COMPLETEDDuowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With HypertensionNCT03267329 · 2017-09-11
COMPLETEDEfficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With HyperlipidemiaNCT03566316 · 2015-11-24
COMPLETEDStudy of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male VolunteersNCT02933658 · 2015-11-01
COMPLETEDCKD-828 (80/5mg) Pharmacokinetic StudyNCT02358824 · 2015-02-01
COMPLETEDAnalysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV InfectionNCT02170246 · 2015-01-28
COMPLETEDTelmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake PopulationNCT02255253 · 2014-10-01
COMPLETEDINTERVENCION TrialNCT02373163 · 2014-09-01
COMPLETEDCKD-828 (80/5mg) Pharmacokinetic StudyNCT02250833 · 2014-09-01
COMPLETEDA Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-RNCT02079805 · 2014-06-01
COMPLETEDTo Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male VolunteersNCT02579356 · 2014-05-01
COMPLETEDDrug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)NCT02152969 · 2014-05-01
COMPLETEDTelmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease PatientsNCT02085265 · 2014-03-01
TERMINATEDTelmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)NCT01928927 · 2014-01-01
COMPLETEDEfficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and HyperlipidemiaNCT01914432 · 2013-11-01
COMPLETEDNon-invasive Haemodynamic Assessment in HypertensionNCT01996085 · 2013-01-01
COMPLETEDA Clinical Trial for People HIV+ Age > 50 at Risk for Heart DiseaseNCT01578772 · 2012-08-01
COMPLETEDHIGH Altitude CArdiovascular REsearch in the ANDESNCT01830530 · 2012-05-01
COMPLETEDTwynsta Study With Lifestyle Modifications in Korean Patients With HypertensionNCT01316419 · 2011-03-01
COMPLETEDComparative Study of the Effects of Telmisartan and NebivololNCT02057328 · 2010-12-01
UNKNOWNTelmisartan 80mg Non-responder TrialNCT01222520 · 2010-10-01
COMPLETEDTelmisartan, Amlodipine and Flow Mediated DilationNCT01180205 · 2010-08-01
UNKNOWNCKD-828 Primary Hypertension Trial(Dose-selection)NCT01128322 · 2010-07-01
COMPLETEDHIV and Fat AccumulationNCT01088295 · 2010-05-01
COMPLETEDAntihypertensive Medications and the Risk of SepsisNCT02248896 · 2010-01-01
COMPLETEDTelmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe HypertensionNCT00926289 · 2009-06-01
COMPLETEDTelmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With SchizophreniaNCT00981526 · 2009-03-01
COMPLETEDTelmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe HypertensionNCT00860262 · 2009-03-01
COMPLETEDConditions being studied
Hypertension63Diabetic Nephropathies3Arterial Hypertension2Diabetes Mellitus, Type 22Dyslipidemia2Essential Hypertension2Hypercholesterolemia2Kidney, Polycystic2Metabolic Syndrome2Acute HIV Infection1Alzheimer's Disease1Atrial Fibrillation1Blood Pressure, High1Breast Cancer1Coronary Arteriosclerosis1Coronary Artery Disease1Diabetes1Diabetes Mellitus Type 2 IRC or NIR1Diabetic Nephropathy Type 21Diseases of the Circulatory System1
Research locations
SeoulSouth Korea16BostonMassachusetts, United States6Los AngelesCalifornia, United States6ClevelandOhio, United States5DaeguSouth Korea5HoustonTexas, United States4MoscowRussia4Saint PetersburgRussia4SevilleSpain4AlbuquerqueNew Mexico, United States3AtlantaGeorgia, United States3AuroraColorado, United States3
Leading sponsors
Boehringer Ingelheim40Chong Kun Dang Pharmaceutical5Addpharma Inc.3Yuhan Corporation3Brigham and Women's Hospital2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2University of California, Los Angeles2Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections1Aristotle University Of Thessaloniki1Bayer1Cairo University1Daewon Pharmaceutical Co., Ltd.1First Affiliated Hospital Xi'an Jiaotong University1IlDong Pharmaceutical Co Ltd1Istituto Auxologico Italiano1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.